S&P 5007,691▲ 0.41%Nasdaq26,431▲ 1.11%Dow Jones51,966▼ 0.07%Nasdaq 10029,529▲ 1.17%VIX18.44▼ 7.75%US Dollar101.97▲ 0.13%Gold spot4,165▲ 0.21%WTI spot101.91▲ 1.04%
Stockholm Exchange · Sweden · Updated after 19 Oct 2026 close

BioInvent International AB

BINV · Stockholm Exchange · prices in SEK
SEK 21.60▼ -1.80 (7.69%)
Research reportHistorical data

About BioInvent International AB

BioInvent International is a Swedish biotechnology company based in Lund that discovers and develops antibody-based medicines for cancer. Its work centres on immuno-oncology, creating antibodies designed to activate the body's immune system against tumours, and it advances these candidates through early clinical testing. The company works with partners in academia and the pharmaceutical industry, and its customers and collaborators are mainly clinical researchers, hospitals and drug developers involved in cancer treatment studies.

BioInvent International AB trades under the code BINV on the Stockholm Exchange in Sweden, with its price quoted in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

49/ 100
Market X-Ray · price-based
Weak price profile
Ranks #481 of 911 on the Stockholm Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Sweden yet.
TrendWeak
39/100
Below its long-term averages and far from its highs.
See the numbers →
Above 200-day average-11.9%
From 52-week high-36.3%
MomentumWeak
48/100
Lagging most stocks on this exchange.
See the numbers →
3-month return-4.2%
6-month return-1.4%
12-month, skipping last month-21.2%
Stability (higher is calmer)Weak
50/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)53.5%
Worst drawdown, 1 year (smaller is calmer)-38.6%
LiquidityFair
66/100
Moderate trading activity.
See the numbers →
Avg daily value traded2.00M SEK
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Sweden when fundamentals data for this market is added. All Sweden stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
19.22 – 34.85
Price is 15% of the way up
Returns
−4.2% 3m · −23.8% 1y
Price returns, dividends not included
RSI (14)
38
Neutral zone

Price chart

52-wk range 19.22 – 34.85 Daily closes, split-adjusted

Signals

50-day average23.14
200-day average24.51
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.84

Technical summary

Daily
Strongly bearish
2 bullish · 2 neutral · 12 bearish
Weekly
Strongly bearish
0 bullish · 1 neutral · 11 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
SMA 1023.05Bearish
EMA 1022.87Bearish
SMA 2022.72Bearish
EMA 2022.87Bearish
SMA 5023.14Bearish
EMA 5023.05Bearish
SMA 10023.73Bearish
EMA 10023.55Bearish
SMA 20024.51Bearish
EMA 20024.87Bearish
Oscillators (daily)
RSI (14)37.97Neutral
MACD (12, 26)-0.01Bearish
Momentum (12)-4.00Bearish
Stochastic %K (14)11.11Bullish
Williams %R (14)-88.89Bullish
CCI (20)-91.71Neutral
Pivot points (classic, last session)
S3
18.50
S2
19.90
S1
20.75
Pivot
22.15
R1
23.00
R2
24.40
R3
25.25
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in SEK. Educational only, not financial advice.